Raymond James Financial Inc. Acquires Shares of 201,020 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Raymond James Financial Inc. bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 201,020 shares of the medical equipment provider's stock, valued at approximately $21,234,000. Raymond James Financial Inc. owned about 0.10% of Zimmer Biomet as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of ZBH. CKW Financial Group lifted its position in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the period. FWG Holdings LLC lifted its position in Zimmer Biomet by 2.9% during the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock valued at $372,000 after purchasing an additional 101 shares during the period. Romano Brothers AND Company lifted its position in Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after purchasing an additional 102 shares during the period. M&T Bank Corp lifted its position in Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after purchasing an additional 108 shares during the period. Finally, Dakota Wealth Management lifted its position in Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after purchasing an additional 122 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Price Performance

ZBH traded down $1.19 during trading on Thursday, hitting $111.72. 1,416,455 shares of the company traded hands, compared to its average volume of 1,489,205. The company has a market cap of $22.24 billion, a PE ratio of 25.11, a P/E/G ratio of 1.95 and a beta of 1.04. The stock's 50-day simple moving average is $106.41 and its two-hundred day simple moving average is $106.93. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business earned $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.86%. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ZBH shares. Raymond James lowered their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays decreased their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.